Breaking News: A New Hope for Refractory Multiple Myeloma?
For patients battling multiple myeloma, especially those whose disease has stubbornly resisted multiple treatments, the search for effective therapies is relentless. But what if there was a new approach that showed promise even in the most challenging cases? That's the question being explored with gintemetostat, an innovative drug that's making waves in the oncology world.
Early results from a phase 1 trial (NCT05651932) are in, and they're offering a glimmer of hope. Gintemetostat, a first-in-class MMSET/NSD2 inhibitor (also known as KTX-1001), has demonstrated encouraging activity and a manageable safety profile in heavily pretreated patients. These findings, presented at the 2025 ASH Annual Meeting, could pave the way for future combination therapies, offering new avenues for those who have exhausted other options.
So, what exactly did the study reveal?
Out of 40 patients treated with gintemetostat, the results were as follows:
- 1 patient achieved a very good partial response.
- 1 patient had a partial response.
- 2 patients experienced a minimal response.
- 12 patients achieved stable disease.
These results are particularly noteworthy because the study focused on a group of patients with relapsed or refractory multiple myeloma, including those with triple-class-refractory disease and high-risk features like the t(4;14) genetic abnormality. As lead author Dr. Saad Usmani, Chief of Myeloma Service at Memorial Sloan Kettering Cancer Center, noted, the drug showed activity even in patients with the t(4;14) genetic abnormality. But here's where it gets controversial: how do we interpret these early responses? Are they enough to warrant excitement, or are more robust results needed?
Safety and Tolerability: A Critical Piece of the Puzzle
No treatment is without its risks, and the safety profile of gintemetostat is crucial to understanding its potential. The phase 1 study revealed that 75% of patients experienced treatment-emergent adverse events (TEAEs) potentially linked to the drug, and 45% experienced grade 3 or higher TEAEs. Dose reductions were necessary for 3 patients due to these events. At the data cutoff date of June 13, 2025, 12 patients remained on treatment. Of the 28 patients who discontinued treatment, the primary reasons were progressive disease (82%), physician decision (7.1%), consent withdrawal (7.1%), and TEAEs (3.6%).
The most common grade 3/4 hematologic TEAEs included:
- Thrombocytopenia (grade 3, 10%; grade 4, 20%)
- Anemia (25% grade 3; 0% grade 4)
- Neutropenia (25% grade 3; 5% grade 4)
- Febrile neutropenia (5% grade 3; 0% grade 4)
The most common grade 3 nonhematologic TEAEs were infections (12.5%) and fatigue (10%).
It's important to note that there were 2 patient deaths during the study, but neither was directly attributed to gintemetostat treatment. One death was due to respiratory failure, and the other to pleural effusion. But this raises the question: Could these side effects be mitigated with careful management, or do they represent a significant hurdle?
Understanding the Science: Why MMSET Matters
But this is the part most people miss: The rationale behind the study is rooted in the biology of multiple myeloma. Overexpression of MMSET (also known as NSD2) is often triggered by the t(4;14) translocation, a genetic abnormality associated with poor outcomes in multiple myeloma patients. Gintemetostat, designed to target and inhibit MMSET, aims to disrupt this process and potentially improve patient outcomes.
The study enrolled 40 patients aged ≥18 years with relapsed or refractory multiple myeloma who had undergone at least 3 prior therapies, including a proteasome inhibitor (PI), an immunomodulatory drug (IMiD), and an anti-CD38 monoclonal antibody. The median age of the patients was 69 years (range, 50–83), with 52.5% being female. The median time since initial diagnosis was 8 years (range, 2–20).
A Closer Look at Patient Characteristics
- 32.5% of patients had extramedullary disease.
- 30% had high-risk multiple myeloma.
- 47.5% of patients had t(4;14) cytogenetic abnormalities.
- The median number of prior lines of therapy was 6.5 (range, 3–25).
- 77.5% of patients had received at least 5 lines of therapy.
- 70% of patients had prior stem cell transplant.
Prior drug classes received included IMiD/PI (100%), anti-CD38 (98%), BCMA CAR-T (42.5%), BCMA-targeted bispecific antibodies (BsAb) and antibody-drug conjugates (57.5%), GPRC5D-targeted BsAb (32.5%), and FcRH5-targeted BsAb (7.5%). Almost all patients (97%) had been exposed to three classes of drugs, and 80% had been exposed to five classes of drugs.
The Road Ahead: What's Next for Gintemetostat?
Dr. Usmani noted that gintemetostat showed a favorable safety and tolerability profile and demonstrated disease control and efficacy. Pharmacodynamic data confirm target engagement, and the next step is to evaluate combinations with proteasome inhibitors, IMiDs, and next-generation CELMoDs such as mezigdomide. So, could gintemetostat be the key to unlocking better outcomes for patients with multiple myeloma? What are your thoughts?
Controversy & Comment Hooks:
- Do you think the early results are promising enough to warrant further investigation?
- What are your thoughts on the safety profile of gintemetostat? Are the side effects manageable?
- How important is it to target the MMSET protein in multiple myeloma treatment?
Let's discuss in the comments below! Your insights are valuable.
